IQVIA Holdings Inc. (NYSE:IQV) Shares Acquired by Creative Planning

Creative Planning grew its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 17.8% in the third quarter, Holdings Channel.com reports. The institutional investor owned 21,013 shares of the medical research company’s stock after buying an additional 3,176 shares during the quarter. Creative Planning’s holdings in IQVIA were worth $4,980,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the business. Canada Pension Plan Investment Board raised its position in shares of IQVIA by 6.6% in the second quarter. Canada Pension Plan Investment Board now owns 3,403,488 shares of the medical research company’s stock valued at $719,634,000 after buying an additional 211,653 shares during the last quarter. Lazard Asset Management LLC grew its holdings in shares of IQVIA by 0.9% in the first quarter. Lazard Asset Management LLC now owns 3,263,944 shares of the medical research company’s stock valued at $825,416,000 after purchasing an additional 30,014 shares during the period. Farallon Capital Management LLC grew its holdings in shares of IQVIA by 3.1% in the second quarter. Farallon Capital Management LLC now owns 2,923,032 shares of the medical research company’s stock valued at $618,046,000 after purchasing an additional 86,870 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in shares of IQVIA by 3.8% in the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,510,685 shares of the medical research company’s stock valued at $634,927,000 after purchasing an additional 92,293 shares during the period. Finally, Capital Research Global Investors grew its holdings in shares of IQVIA by 7.2% in the first quarter. Capital Research Global Investors now owns 2,138,802 shares of the medical research company’s stock valued at $540,882,000 after purchasing an additional 143,533 shares during the period. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on IQV shares. Evercore ISI dropped their price objective on shares of IQVIA from $270.00 to $265.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th. UBS Group upped their price objective on shares of IQVIA from $295.00 to $300.00 and gave the company a “buy” rating in a report on Tuesday, July 23rd. Jefferies Financial Group lowered shares of IQVIA from a “buy” rating to a “hold” rating and dropped their price objective for the company from $266.00 to $242.00 in a report on Wednesday, July 24th. Argus raised shares of IQVIA to a “strong-buy” rating in a report on Wednesday, July 31st. Finally, Barclays lowered their target price on shares of IQVIA from $275.00 to $260.00 and set an “overweight” rating for the company in a research note on Tuesday, October 15th. Five investment analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $267.27.

Insider Activity at IQVIA

In related news, insider Eric Sherbet sold 1,300 shares of the firm’s stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total value of $320,229.00. Following the sale, the insider now owns 19,536 shares of the company’s stock, valued at $4,812,302.88. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.60% of the stock is owned by corporate insiders.

IQVIA Stock Down 7.3 %

Shares of IQV opened at $211.71 on Friday. The stock has a market capitalization of $38.59 billion, a PE ratio of 27.49, a P/E/G ratio of 2.22 and a beta of 1.49. IQVIA Holdings Inc. has a 1 year low of $167.42 and a 1 year high of $261.73. The company has a debt-to-equity ratio of 1.80, a quick ratio of 0.85 and a current ratio of 0.85. The company’s 50-day simple moving average is $238.71 and its 200-day simple moving average is $230.92.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Monday, July 22nd. The medical research company reported $2.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.57 by $0.07. The business had revenue of $3.81 billion for the quarter, compared to analysts’ expectations of $3.79 billion. IQVIA had a net margin of 9.39% and a return on equity of 28.59%. The business’s quarterly revenue was up 2.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.22 earnings per share. Analysts forecast that IQVIA Holdings Inc. will post 10.25 earnings per share for the current fiscal year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.